GlassScriptPhysician profile
John Elliott Christie
NPI 1760529648
$763.24
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $193 · 2021: $351.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $184.95 | 2019-2021 | |
| Amgen INC. | $90.32 | 2021 | |
| Eisai INC. | $84.95 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $81.24 | 2020-2021 | |
| Allergan, INC. | $75.08 | 2019-2020 | |
| Pfizer INC. | $65.62 | 2019 | |
| Abbvie INC. | $51.22 | 2021 | |
| Novo Nordisk INC | $42.39 | 2021 | |
| Jazz Pharmaceuticals INC. | $37.30 | 2019-2020 | |
| Shire North American Group INC | $21.97 | 2019 | |
| Horizon Therapeutics Plc | $14.93 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Christie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.